Compare T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
T-Rex 2X Inverse MSTR Daily Target ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? T-Rex 2X Inverse MSTR Daily Target ETF trades at $3.19 (market cap $88.87M), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 54.9× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| MSTZ | TVTX | |
|---|---|---|
Market Cap | $88.87M | $4.88B |
Volume | 52,792,380 | 1,668,577 |
Sector | Leveraged / Inverse | Health |
52-Week High | $27.92 | $67.52 |
52-Week Low | $2.29 | $26.79 |
Typical Hold Time | 8 Days | 0 Days |
Enterprise Value | — | $5.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSTZ trades at $2.69 with minimal daily movement (+0.37%). Technical indicators show a bearish bias with moving averages signaling caution, while oscillators remain neutral. The stock lacks available fundamental data for key valuation and profitability metrics, creating uncertainty about its financial health. Recent ETF coverage highlights performance trends but provides limited company-specific insights.
The outlook remains uncertain due to missing financial data and bearish technical signals. Investment opportunity hinges on future earnings visibility and improved technical momentum. Key risks include lack of financial transparency and weak technical positioning that could pressure the stock toward support levels near $2.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
